217 related articles for article (PubMed ID: 22560614)
1. Raf inhibitors target ras spatiotemporal dynamics.
Cho KJ; Kasai RS; Park JH; Chigurupati S; Heidorn SJ; van der Hoeven D; Plowman SJ; Kusumi A; Marais R; Hancock JF
Curr Biol; 2012 Jun; 22(11):945-55. PubMed ID: 22560614
[TBL] [Abstract][Full Text] [Related]
2. Ras nanoclusters: a new drug target?
Cho KJ; Hancock JF
Small GTPases; 2013; 4(1):57-60. PubMed ID: 23419283
[TBL] [Abstract][Full Text] [Related]
3. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
[TBL] [Abstract][Full Text] [Related]
4. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
[TBL] [Abstract][Full Text] [Related]
5. The Mystery of Rap1 Suppression of Oncogenic Ras.
Nussinov R; Jang H; Zhang M; Tsai CJ; Sablina AA
Trends Cancer; 2020 May; 6(5):369-379. PubMed ID: 32249186
[TBL] [Abstract][Full Text] [Related]
6. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.
Heidorn SJ; Milagre C; Whittaker S; Nourry A; Niculescu-Duvas I; Dhomen N; Hussain J; Reis-Filho JS; Springer CJ; Pritchard C; Marais R
Cell; 2010 Jan; 140(2):209-21. PubMed ID: 20141835
[TBL] [Abstract][Full Text] [Related]
7. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
Ming Z; Lim SY; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
[TBL] [Abstract][Full Text] [Related]
8. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.
Jaiswal BS; Janakiraman V; Kljavin NM; Eastham-Anderson J; Cupp JE; Liang Y; Davis DP; Hoeflich KP; Seshagiri S
PLoS One; 2009 May; 4(5):e5717. PubMed ID: 19492075
[TBL] [Abstract][Full Text] [Related]
9. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF.
Hu J; Yu H; Kornev AP; Zhao J; Filbert EL; Taylor SS; Shaw AS
Proc Natl Acad Sci U S A; 2011 Apr; 108(15):6067-72. PubMed ID: 21441104
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidylinositol 3-kinase requirement in activation of the ras/C-raf-1/MEK/ERK and p70(s6k) signaling cascade by the insulinomimetic agent vanadyl sulfate.
Pandey SK; Théberge JF; Bernier M; Srivastava AK
Biochemistry; 1999 Nov; 38(44):14667-75. PubMed ID: 10545192
[TBL] [Abstract][Full Text] [Related]
11. Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.
Mooz J; Oberoi-Khanuja TK; Harms GS; Wang W; Jaiswal BS; Seshagiri S; Tikkanen R; Rajalingam K
Sci Signal; 2014 Aug; 7(337):ra73. PubMed ID: 25097033
[TBL] [Abstract][Full Text] [Related]
12. Analyses of the oncogenic BRAF
Cope NJ; Novak B; Liu Z; Cavallo M; Gunderwala AY; Connolly M; Wang Z
J Biol Chem; 2020 Feb; 295(8):2407-2420. PubMed ID: 31929109
[TBL] [Abstract][Full Text] [Related]
13. ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.
Rebocho AP; Marais R
Oncogene; 2013 Jun; 32(26):3207-12. PubMed ID: 22926515
[TBL] [Abstract][Full Text] [Related]
14. LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
Monaco KA; Delach S; Yuan J; Mishina Y; Fordjour P; Labrot E; McKay D; Guo R; Higgins S; Wang HQ; Liang J; Bui K; Green J; Aspesi P; Ambrose J; Mapa F; Griner L; Jaskelioff M; Fuller J; Crawford K; Pardee G; Widger S; Hammerman PS; Engelman JA; Stuart DD; Cooke VG; Caponigro G
Clin Cancer Res; 2021 Apr; 27(7):2061-2073. PubMed ID: 33355204
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
Peng SB; Henry JR; Kaufman MD; Lu WP; Smith BD; Vogeti S; Rutkoski TJ; Wise S; Chun L; Zhang Y; Van Horn RD; Yin T; Zhang X; Yadav V; Chen SH; Gong X; Ma X; Webster Y; Buchanan S; Mochalkin I; Huber L; Kays L; Donoho GP; Walgren J; McCann D; Patel P; Conti I; Plowman GD; Starling JJ; Flynn DL
Cancer Cell; 2015 Sep; 28(3):384-98. PubMed ID: 26343583
[TBL] [Abstract][Full Text] [Related]
16. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.
Wang P; Laster K; Jia X; Dong Z; Liu K
Mol Cancer; 2023 Dec; 22(1):208. PubMed ID: 38111008
[TBL] [Abstract][Full Text] [Related]
17. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
18. Electrostatic interactions positively regulate K-Ras nanocluster formation and function.
Plowman SJ; Ariotti N; Goodall A; Parton RG; Hancock JF
Mol Cell Biol; 2008 Jul; 28(13):4377-85. PubMed ID: 18458061
[TBL] [Abstract][Full Text] [Related]
19. RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma.
Dorard C; Estrada C; Barbotin C; Larcher M; Garancher A; Leloup J; Beermann F; Baccarini M; Pouponnot C; Larue L; Eychène A; Druillennec S
Nat Commun; 2017 May; 8():15262. PubMed ID: 28497782
[TBL] [Abstract][Full Text] [Related]
20. Conformation-specific inhibitors of activated Ras GTPases reveal limited Ras dependency of patient-derived cancer organoids.
Wiechmann S; Maisonneuve P; Grebbin BM; Hoffmeister M; Kaulich M; Clevers H; Rajalingam K; Kurinov I; Farin HF; Sicheri F; Ernst A
J Biol Chem; 2020 Apr; 295(14):4526-4540. PubMed ID: 32086379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
